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Abstract
Background and Purpose—The purpose of this study was to collect precise information on 
the typical imaging decisions given specific clinical acute stroke scenarios. Stroke centers 
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worldwide were surveyed regarding typical imaging used to work up representative acute stroke 
patients, make treatment decisions, and willingness to enroll in clinical trials.
Methods—STroke Imaging Research and Virtual International Stroke Trials Archive-Imaging 
circulated an online survey of clinical case vignettes through its website, the websites of national 
professional societies from multiple countries as well as through email distribution lists from 
STroke Imaging Research and participating societies. Survey responders were asked to select the 
typical imaging work-up for each clinical vignette presented. Actual images were not presented to 
the survey responders. Instead, the survey then displayed several types of imaging findings offered 
by the imaging strategy, and the responders selected the appropriate therapy and whether to enroll 
into a clinical trial considering time from onset, clinical presentation, and imaging findings. A 
follow-up survey focusing on 6 h from onset was conducted after the release of the positive 
endovascular trials.
Results—We received 548 responses from 35 countries including 282 individual centers; 78% of 
the centers originating from Australia, Brazil, France, Germany, Spain, United Kingdom, and 
United States. The specific onset windows presented influenced the type of imaging work-up 
selected more than the clinical scenario. Magnetic Resonance Imaging usage (27–28%) was 
substantial, in particular for wake-up stroke. Following the release of the positive trials, selection 
of perfusion imaging significantly increased for imaging strategy.
Conclusions—Usage of vascular or perfusion imaging by Computed Tomography or Magnetic 
Resonance Imaging beyond just parenchymal imaging was the primary work-up (62–87%) across 
all clinical vignettes and time windows. Perfusion imaging with Computed Tomography or 
Magnetic Resonance Imaging was associated with increased probability of enrollment into clinical 
trials for 0–3 h. Following the release of the positive endovascular trials, selection of endovascular 
only treatment for 6 h increased across all clinical vignettes.
Keywords
Computed Tomography scan; clinical trial; ischemic stroke; Magnetic Resonance Imaging; stroke; 
thrombolysis
Introduction
The use of imaging in treatment and clinical trial enrollment decision-making has been well 
investigated.1–11 The current recommended uses of imaging in stroke clinical trials were put 
forth in the Acute Stroke Imaging Research Roadmap II by the STroke Imaging Research 
(STIR) and Virtual International Stroke Trials Archive (VISTA)-Imaging groups.12 
Specifically, these uses outlined the selection of patients with imaging-confirmed diagnosis 
of stroke, selection of appropriate patients with treatment-relevant acute imaging target 
(TRAIT), and exclusion of patients based on imaging-defined futility of therapeutic 
intervention.12 However, some multi center studies of acute stroke trial imaging 
practicalities suggest that the substantial enthusiasm to use Magnetic Resonance Imaging 
(MRI) including perfusion imaging in trials, and greater availability of MRI in stroke 
centers, is not matched by actual use in practice.13,14
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To better inform trial design, more precise information regarding the clinician's preferences 
with respect to typical imaging of standard acute stroke patients as a function of clinical 
presentation across a spectrum of scenarios encountered in daily practice would be useful. 
We surveyed stroke centers worldwide to quantify the consistency of typical imaging 
selection in acute stroke treatment decisions and willingness to enroll into clinical trials. We 
attempted to understand the amount of consistency across centers when imaging-based 
definitions were applied. We included clinical vignettes with varying stroke severity and 
across multiple time windows to understand the impact of these factors in terms of selection 
of imaging work-up, treatment, and trial enrolment decisions. Multiple imaging modalities 
and typical findings were included in the survey to allow for specific imaging optimization 
for each clinical vignette. This has been previously studied; however, it has been limited as 
far as scope including the number of clinical scenarios considered, imaging protocols, and 
participating stroke centers.15
Our study attempted to collect data on imaging selection practices worldwide to identify 
some of the unresolved issues with these biomarkers.12 These issues included the usage of 
MRI versus Computed Tomography (CT) on patient selection, the added value of vascular 
and perfusion imaging, the effect of additional imaging on treatment and enrollment rates, 
and whether imaging selection varied depending on the time window and clinical 
presentation.
Methods
STIR and VISTA circulated an online survey of clinical vignettes during the summer of 
2014 through its website (https://stir.seton.org) and its email distribution list, through the 
websites and email distribution lists of national professional societies from multiple 
countries including Australia, Brazil, France, Germany, Italy, South Korea, Spain, United 
Kingdom, and United States (American Society of Neurology, British Society of 
Neuroradiology, European Stroke Organization, etc). The survey was distributed in 
preparation for and prior to the Thrombolysis and Thrombectomy in Acute Stroke Treatment 
meeting. The initial survey was conducted prior to the release of the positive results of the 
endovascular trials including MR CLEAN (a Multi center Randomized CLinical trial of 
Endovascular treatment for Acute ischemic stroke in the Netherlands).16 We circulated 
using the same mechanisms described above a follow-up survey after the release of the 
positive endovascular trials16 to understand the potential impact on treatment and enrollment 
rates.
The survey included 14 unique clinical vignettes covering up to 21 typical scenarios with 
varying imaging findings encountered in daily practice. Each clinical vignette displayed the 
patient's age, onset time window, a brief description of clinical symptoms, and the 
corresponding National Institutes of Health Stroke Scale (NIHSS) score. There were four 
clinical descriptions, linked to four stroke onset-to-presentation times, namely 0–3, 6, or 10 
h or wake-up, save for two scenarios. The follow-up survey included the same four clinical 
descriptions at 6 h only. Table 1 contains the clinical scenarios descriptions. The responder 
was presented with all scenarios across the same time window before being presented with 
the next time window.
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Responders were then asked what typical imaging they would request in a standard patient 
with the clinical description just displayed. Actual images were not presented to the survey 
responders. Responders were allowed to select as many imaging options as applicable across 
multiple modalities and parameters. The imaging options provided for each clinical vignette 
were: (a) CT non-contrast head; (b) Computed Tomography Angiography (CTA) head and 
neck; (c) CT perfusion; (d) Brain MR including Diffusion-Weighted Imaging (DWI), FLuid 
Attenuated Inversion Recovery (FLAIR), and Gradient Recalled Echo (GRE)/Susceptibility-
Weighted Imaging (SWI), Magnetic Resonance Angiography (MRA) of the head; (e) 
Gadolinium (GAD) MRA of the aortic arch and cervical arteries, and/or (f). MR perfusion 
(Dynamic Susceptibility Contrast (DSC) or Arterial Spin Labeling (ASL)). Based on the 
specific imaging options selected, the corresponding modality specific imaging findings 
were displayed to the responder. If parenchymal imaging was selected, then the DWI lesion 
volume or CT Alberta Stroke Program Early CT Score (ASPECTS) was disclosed for MRI 
or CT, respectively. For time windows greater than 0–3 h, a possible subtle FLAIR 
abnormality in the imaging findings was also included. If vascular imaging was selected, 
then the location of the occlusion (Internal Carotid Artery (ICA), M1, M2, basilar, or no 
occlusion) was disclosed. If perfusion imaging was selected, then the size: large, small, or 
no penumbra including the penumbral volume, percent of the ischemic volume relative to 
the total perfusion deficit volume, total perfusion deficit volume, and specific penumbral 
location in case of basilar artery territory involvement were disclosed. All applicable 
imaging findings were displayed to the responder at once.
Responders were then asked the typical treatment they would administer in a standard 
patient with the imaging findings just displayed. Responders were asked to select only one 
option from the treatment options: (1) no revascularization therapy, (2) intravenous (IV) tPA 
alone, (3) endovascular/intra-arterial (IA) alone, or (4) IV tPA possibly followed by 
endovascular/IA. Next, responders were asked whether they would enroll this patient in an 
image-guided clinical trial comparing endovascular and/or IV tPA versus best medical 
therapy with yes or no options. Responders were not allowed to go back to change their 
answers to any clinical vignette questions. Therefore, after specific imaging findings were 
provided, the responders were not able to modify their treatment or clinical enrollment 
decisions for prior clinical vignettes. Responders were not required to answer all clinical 
vignettes, however, complete versus partial responses were tracked.
As many interested responders at each participating center were asked to answer the survey. 
At the end of the survey, responders were asked if they belonged to a stroke network, a 
collaborative group of stroke centers, and if so to specify, if the current work-up of their 
acute ischemic stroke patients used the imaging modality that they considered to be optimal 
or the imaging modality that is practical, as well as their specialty: stroke neurologist, i.e. 
medical specialty dealing with stroke, stroke physician, emergency physician, diagnostic 
neuroradiologist, interventionalist, and diagnostic and interventional neuroradiologist or 
other.
Unless noted otherwise for the majority of results presented in this study, only one response 
from each participating center was included. One response per center was included to weigh 
results equally across centers rather than to have results biased toward the highest 
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responding centers. If more than one response was provided by a center, then one response 
was selected from all complete responses across all specialties. The selection was performed 
in blinded fashion to the actual answers of the clinical vignettes. The survey software 
automatically tracked a status of “complete” or “partial” for each response based on whether 
the responder answered all of the clinical vignettes. If an individual center had both 
complete and partial responses, then the complete response was chosen. If more than one 
complete response per center was available, then just one was chosen blinded to the actual 
answers including specialty. Participating centers were asked to provide their site name and 
country with responder name as optional. In addition, all responses were automatically 
tracked by the survey software based on location parameters: city, state, country, and 
network location: internet protocol address. This tracking information was used as necessary 
to identify multiple responses from individual centers.
Nonparametric binomial tests were used to calculate significance of probability between 
responses with IBM SPSS Statistics Version 19.0.
Results
We received 548 responses from 35 countries including 282 individual centers; 78% of the 
centers originating from Australia, Brazil, France, Germany, Spain, United Kingdom, and 
United States. Specialty was not reported by 45% of the 548 responses. Of the remaining 
that reported specialty, stroke neurologists were the primary responders (39%) with the 
remaining responders by stroke physician (5%), emergency physician (1%), diagnostic 
neuroradiologist (4%), interventionalist (1%), diagnostic and interventional neuroradiologist 
(5%), and other (1%). Approximately 450 individuals were emailed and asked to respond to 
the surveys. The subsequent analyses were limited to one representative response from each 
of the 282 individual centers unless otherwise specified. Of the 282 responses, 56% were 
from neurologists, 24% were from the other six specialties, and 20% did not specify. The 
representative response rate by country is provided for both surveys (supplemental Table I). 
Of the 160 responders who answered the stroke network question, 49% reported yes to 
belonging to one whereas 51% reported no. Of the 201 responders who answered the 
optimal versus practical imaging modality usage, 44% indicated that they were using the 
optimal imaging modality whereas 56% indicated that they were using the practical imaging 
modality.
For the follow-up survey, we received 202 responses from 22 countries including 119 
individual centers: 73% of the centers originating from Australia, France, Germany, Japan, 
The Netherlands, South Korea, United Kingdom, and United States. In comparison with the 
original survey, 76% of the same centers responded to the follow-up survey. Of the 119 
responses, 60% were from neurologists, 28% were from the other six specialties, and 12% 
did not specify.
Table 1 contains the breakdown of CT versus MRI selection across the four clinical 
scenarios and time windows. The majority of responders (65–71%) selected CT rather than 
MRI across all clinical scenarios in the 0 - to 3-h time window (p < 0.0001). The selection of 
MRI was substantial in the time windows of 6 h, 10 h, and wake-up stroke, especially if the 
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CT followed by MRI option is accounted for, even within the 0–3 window. For wake-up 
stroke, the selection of MRI or combination CT and MRI (56–59%) was higher than CT 
only selection (41–44%, p=0.030, 0.008 for clinical scenarios #1 and #4). Responders 
selected both CT and MRI for the imaging strategy rather than just one modality (21–31%). 
Overall, the specific onset windows influenced the type of imaging work-up selected more 
than the clinical scenario. For the follow-up survey of 6 h, the imaging strategy did not 
change substantially across clinical scenarios, but there was a minor trend for increased MRI 
only selection (2–6%).
Table 2 reports the specific selections of parenchymal, vascular, and perfusion imaging 
using either CT or MRI across the four clinical scenarios and time windows. Usage of 
perfusion imaging increased with time window across the majority of clinical scenarios 
except at 10 h, reaching a maximum with wake-up stroke (49–59%, p=0.010 for wake-up). 
Vascular imaging was consistently highest (32–38%) at 0–3 h across all clinical scenarios 
compared with the other time windows. The follow-up survey for 6 h demonstrated an 
increase (7–13%) in the selection of perfusion imaging (CT or MRI) and a decrease (5–
11%) in parenchymal only imaging (CT or MRI) across all clinical scenarios.
Tables 3 and 4 contain the treatment decisions across clinical scenarios and time windows. 
For scenarios with no penumbra, small penumbra or normal perfusion, no treatment was the 
major selection (37–67%). No treatment was also the primary selection at 10 h for large and 
small penumbra scenarios (54–71%). For 0- to 3-h time window, combination therapy (IV 
tPA possibly followed by endovascular/IA) dominated the clinical scenarios with large 
penumbra (59–67%). In contrast for the scenarios with M2 occlusion with small penumbra 
(42%) or no vascular occlusion and normal perfusion (38%), IV only dominated in 0–3 h but 
did not reach 100%. Endovascular treatment dominated at 6 h for scenarios with large 
penumbra and basilar artery occlusion (35–39%). For wake-up stroke, none (46%) 
dominated for small penumbra. The follow-up survey results for 6 h demonstrated an 
increase in endovascular only treatment (6–15%, p=0.01 for clinical scenarios #1 (large 
penumbra, M1), #2 (small penumbra, M1), and #3 (small penumbra, M2)).
In comparison, supplemental Tables II and III contain the treatment decisions when using 
CT only selections including just non-contrast or multiparametric. For responses where CT 
only was used for imaging, treatment selection did not vary compared with results reported 
in Tables 3 and 4. The follow-up survey results for 6 h reflected an increase in endovascular 
only treatment (4–21%, p < 0.001 for clinical scenario #2 (small penumbra, M1)). In 
supplemental Tables IV and V where MRI only was used, endovascular treatment (48%) did 
dominate at 6 h for scenarios with large penumbra in contrast to CT only decisions. Also, in 
wake-up stroke with large penumbra using MRI, combination treatment dominated (45%) 
with endovascular still as the primary treatment for basilar artery occlusion (48%). Contrary 
to CT only, MRI only selection yielded minimal to no increase in the endovascular only 
treatment with one exception, an 11% increase for clinical scenario #3 (small penumbra, 
M2).
Supplemental Tables VI and VII summarize the treatment decisions when perfusion imaging 
using CT or MRI was included. The selection of combination treatment for large penumbra 
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increased when using perfusion imaging in 0–3 h whether using CT or MRI. Usage of 
perfusion imaging (CT or MRI) yielded various results with the follow-up survey for 
endovascular only treatment selection with the only significant increase of 13% for clinical 
scenario #3 (small penumbra, M2, p < 0.01). For the scenarios with small infarct, IV only 
treatment dominated in 0–3 h for parenchymal only imaging decisions; however, selection 
of combination therapy dominated once vascular or perfusion imaging was included. None 
was the major treatment selection at 6 h (50–98%) across all clinical scenarios when using 
parenchymal only imaging. Once perfusion imaging was added, endovascular therapy 
dominated for large penumbra and basilar artery occlusion scenarios (50–61%). For 
parenchymal only imaging decisions, endovascular only treatment decisions for 6 h 
increased significantly (6–17%) across clinical scenarios #1, #2 with small infarct, p < 
0.001, and #4 with hemiparesis, p < 0.001.
No treatment was the exclusive selection at 10 h for scenarios when parenchymal only 
imaging was used. Once vascular or perfusion imaging was selected, endovascular therapy 
was selected for basilar artery occlusion (28–69%). Similarly for wake-up stroke, 
parenchymal only imaging lead to none as the primary treatment selection. Once vascular 
and perfusion imaging was added, endovascular only (7–58%) and combination therapy (7–
41%) increased. With the follow-up survey results for 6 h when vascular imaging was 
added, endovascular only (16–32%) decisions increased even further across all scenarios, in 
particular, for small infarct clinical scenarios #1 (M1, p<0.01; ICA, p<0.001), #2 (p<0.01), 
#3 (M1, p<0.0001), and basilar artery occlusion clinical scenario #4 (p<0.0001). Treatment 
decisions when using parenchymal only, and parenchymal and vascular using CT or MRI 
are summarized in supplemental Tables VIII, IX, X, and XI. As noted in the table heads, for 
the basilar artery occlusion scenario (#4), if parenchymal imaging only using either CT or 
MRI was selected, then it was not actually known to be a basilar artery occlusion.
Table 5 breaks down the clinical trial enrollment decisions across clinical scenario and time 
window. Positive enrollment rate was highest for ICA/M1 occlusion with large penumbra 
(58–66%) for 0–3 h. There was still willingness (50–55%) to enroll for this scenario at 6 h 
and wake-up. Equipoise was demonstrated consistently for M1/small penumbra, normal 
perfusion, and basilar artery occlusion scenarios across all time windows except at 10 h. At 
10 h, rates were reduced further, demonstrating unwillingness to enroll in this time window. 
For the follow-up survey of 6 h, willingness to enroll across small penumbra scenarios 
increased (10–23%, p < 0.001 for clinical scenario #3 (small penumbra, M2)).
In comparison, supplemental Tables XII and XIII contain the clinical trial enrollment 
decisions when using CT only or MRI only selections. In supplemental Table XII, positive 
enrollment rates across time windows were consistent with the results reported in Table 5. 
However, in supplemental Table XIII, for responses where MRI only was used for imaging, 
positive enrollment rates across all time windows were higher except at 10 h and for basilar 
artery occlusion scenarios across all time windows. There was 100% agreement to not to 
enroll normal perfusion cases when using MRI only for clinical scenario #3.
For comparison with Table 5, supplemental Tables XIV and XV contain the clinical trial 
enrollment decisions when using parenchymal only, and parenchymal and vascular imaging 
Luby et al. Page 7
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
using CT or MRI. The enrollment decisions were comparable with those summarized in 
Table 5. However, Table 6 contains the clinical trial enrollment decisions including 
perfusion imaging using CT or MRI. Similar to MRI only based decisions, positive 
enrollment rates across all time windows were higher for perfusion imaging-based decisions. 
Positive enrollment rates were maximized (53–79%) for wake-up stroke across all scenarios 
when perfusion imaging was required. For the follow-up survey of 6 h, willingness to enroll 
across large penumbra scenarios decreased significantly (24–30%, p < 0.001) when 
perfusion imaging (CT or MRI) was selected. Conversely, there was a significant increase in 
willingness to enroll in clinical scenario #3 (M2, small penumbra) (18%, p < 0.01).
Discussion
One response per center was included to weigh results equally across centers rather than 
have results biased toward the highest responding centers. However, to illustrate the 
differences between all responses and individual responses, the percentages are reported for 
282 (versus range of all 548) centers below.
The typical imaging modality selected was CT in making treatment decisions across all 
clinical vignettes and time windows. For instance, imaging strategy varied for 0–3 h versus 
all the other time windows. MRI selection, or CT followed by MRI, was substantial, nearly 
50% (48–58%) for the 6-h window regardless of the clinical scenario. This trend for MRI 
selection increased slightly following the release of the positive endovascular trials. Even for 
the 0- to 3-h window, it was approximately 30% (27–36%). MRI only usage (27–28% (31–
32%)) was substantial for wake-up stroke. The design of future image-guided trials in wake-
up stroke should consider MRI-based imaging protocols when dependent TRAITs are 
required.12
The specific onset windows presented influenced the type of imaging work-up selected more 
than the clinical scenarios. This is probably due to the trend of multiparametric imaging 
being selected regardless of clinical scenario. Usage of vascular or perfusion imaging by CT 
or MRI beyond just parenchymal imaging was the primary work-up (62–87% (70–90%)) 
across all clinical vignettes and time windows. For the clinical scenarios of small infarct and 
large penumbra, 59–67% (56–67%) of responders selected IV tPA possibly followed by 
endovascular. When selecting IV tPA, 75% (64–67%) of these responders selected vascular 
or perfusion imaging in the 0- to 3-h window to make the treatment decision. Likewise for 
the clinical scenarios without early improvement, with small infarct and small penumbra, 
42–54% (34–47%) of responders selected IV tPA alone. When selecting IV tPA alone, 81% 
(78%) of these responders selected vascular or perfusion imaging, in the 0- to 3-h window. 
There was an increase in selection of endovascular only treatment at 6 h following the 
release of the endovascular trials but specific to large penumbra, M1 occlusion or small 
penumbra, M1 or M2 occlusion. However, at 10 h, the majority of responders (54–71% (64–
86%)) chose not to treat except in the case of basilar artery occlusion. The majority of these 
responders (62–63% (61–63%)) still selected multiparametric imaging when making the 
treatment decisions.
Luby et al. Page 8
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Perfusion imaging with CT or MRI was associated with increased probability of enrollment 
into clinical trials across 0–3 and 6 h. More than 2/3 responders would enroll patients with 
treatable penumbra into an image-guided clinical trial comparing endovascular (± IV tPA) 
versus IV tPA alone when perfusion imaging was selected. Compared with perfusion 
imaging with CT or MRI, selection of MRI only including parenchymal, vascular, or 
perfusion imaging was associated with comparable enrollment rates into clinical trials across 
0–3 and 6 h. Further with the release of the positive endovascular trials, the selection of 
perfusion imaging increased at 6 h with a decrease in parenchymal only imaging. This 
suggests an overall willingness to utilize multiparametric CT or MRI when enrolling 
patients, in particular, small penumbra cases that need further investigation for promising 
therapies.
There are limitations to the survey and the results generated. Even though the survey was 
emailed indistinctly to unselected member listings of professional societies worldwide, the 
responders did not fully represent the medical community involved in acute stroke imaging 
work-up decisions. For instance, the majority of responders were neurologists, which is not 
representative of all the specialties. Furthermore, the majority of results (78%) were from 
seven countries limiting the generality of the findings. Although we tried to reach as wide a 
range of centers as possible with the survey, the responders are likely to represent 
enthusiasts and academic centers, and, therefore, may not reflect more common approaches 
to imaging or treatment decisions in stroke in non-expert or less interested centers. Further 
when centers are actively enrolling into clinical trials, the default imaging protocols are 
likely comprehensive already. In addition, imaging selections were potentially biased due to 
known efficacy of treatments, rather than imaging selections guiding these decisions. For 
instance, the initial survey was conducted prior to the release of the positive results of the 
endovascular trials including MR CLEAN. Given the positive results of these trials, the 
responses to the treatment decisions posed in the survey for the onset time window of 6 h 
were expected to change, and as a result, a follow-up survey was conducted. The majority of 
responses (76%) from the follow-up survey were from the same centers as the initial survey. 
However, responders were not required to enter their individual name in the survey and the 
majority did not. Therefore, it was not feasible to link and compare responses from 
individuals for the two surveys. Furthermore, there were still some geographical differences 
and a smaller response rate in the follow-up survey, potentially limiting the global 
representation of the results. The scope of the survey was limited to acute treatment and 
clinical trial enrollment decisions and did not address secondary prevention practices.
In conclusion, usage of vascular or perfusion imaging by CT or MRI beyond just 
parenchymal imaging was the primary work-up across all clinical vignettes and time 
windows. MRI usage was substantial, in particular, for wake-up stroke. Following the 
release of the positive trials, selection of perfusion imaging significantly increased for 
imaging strategy. Selection of endovascular only treatment for 6 h increased across all 
clinical vignettes, in response to the positive results of the endovascular trials. To conclude, 
the results from these surveys are intended to serve in the design of future image-guided 
trials.
Luby et al. Page 9
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
STIR\VISTA Imaging Steering Committee: Gregory W. Albers, Stephen M. Davis, Geoffrey A. Donnan, Marc 
Fisher, Anthony J. Furlan, James C. Grotta, Werner Hacke, Dong-Wha Kang, Chelsea Kidwell, Walter J. 
Koroshetz, Kennedy R. Lees, Michael H. Lev, David S. Liebeskind, A. Gregory Sorensen, Vincent N. Thijs, Götz 
Thomalla, Steven J. Warach, Joanna M. Wardlaw, and Max Wintermark.
Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or 
publication of this article: This work was supported by Seton/UT Southwestern Clinical Research Institute of 
Austin, Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Austin, TX, USA and 
the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), 
Bethesda, MD, USA.
References
1. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with 
intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, 
NINDS, and EPITHET trials. Lancet. 2010; 375:1695–1703. [PubMed: 20472172] 
2. Baron JC. Mapping the ischaemic penumbra with pet: Implications for acute stroke treatment. 
Cerebrovasc Dis. 1999; 9:193–201. [PubMed: 10393405] 
3. Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke 
therapy. Lancet Neurol. 2009; 8:261–269. [PubMed: 19233036] 
4. Wardlaw JM, Dorman PJ, Lewis SC, Sandercock PA. Can stroke physicians and neuroradiologists 
identify signs of early cerebral infarction on CT? J Neurol Neurosurg Psychiatry. 1999; 67:651–
653. [PubMed: 10519873] 
5. Muir KW, Baird-Gunning J, Walker L, Baird T, McCormick M, Coutts SB. Can the ischemic 
penumbra be identified on noncontrast CT of acute stroke? Stroke. 2007; 38:2485–2490. [PubMed: 
17673708] 
6. Parsons MW, Pepper EM, Bateman GA, Wang Y, Levi CR. Identification of the penumbra and 
infarct core on hyperacute noncontrast and perfusion CT. Neurology. 2007; 68:730–736. [PubMed: 
17339580] 
7. Muir KW, Halbert HM, Baird TA, McCormick M, Teasdale E. Visual evaluation of perfusion 
computed tomography in acute stroke accurately estimates infarct volume and tissue viability. J 
Neurol Neurosurg Psychiatry. 2006; 77:334–339. [PubMed: 16239323] 
8. Gasparotti R, Grassi M, Mardighian D, Frigerio M, Pavia M, Liserre R, et al. Perfusion CT in 
patients with acute ischemic stroke treated with intra-arterial thrombolysis: Predictive value of 
infarct core size on clinical outcome. AJNR Am J Neuroradiol. 2009; 30:722–727. [PubMed: 
19164437] 
9. Jackson D, Earnshaw SR, Farkouh R, Schwamm L. Cost-effectiveness of CT perfusion for selecting 
patients for intravenous thrombolysis: A US hospital perspective. AJNR Am J Neuroradiol. 2010; 
31:1669–1674. [PubMed: 20538823] 
10. Hopyan J, Ciarallo A, Dowlatshahi D, Howard P, John V, Yeung R, et al. Certainty of stroke 
diagnosis: Incremental benefit with CT perfusion over noncontrast CT and CT angiography. 
Radiology. 2010; 255:142–153. [PubMed: 20308452] 
11. Lin K, Do KG, Ong P, Shapiro M, Babb JS, Siller KA, et al. Perfusion CT improves diagnostic 
accuracy for hyperacute ischemic stroke in the 3-hour window: Study of 100 patients with 
diffusion MRI confirmation. Cerebrovasc Dis. 2009; 28:72–79. [PubMed: 19468218] 
12. Wintermark M, Albers GW, Broderick JP, Demchuk AM, Fiebach JB, Fiehler J, et al. Acute stroke 
imaging research roadmap II. Stroke. 2013; 44:2628–2639. [PubMed: 23860298] 
13. Wardlaw JM, Muir KW, Macleod MJ, Weir C, McVerry F, Carpenter T, et al. Clinical relevance 
and practical implications of trials of perfusion and angiographic imaging in patients with acute 
Luby et al. Page 10
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
ischaemic stroke: A multicentre cohort imaging study. J Neurol Neurosurg Psychiatry. 2013; 
84:1001–1007. [PubMed: 23644501] 
14. Schellinger PD, Bryan RN, Caplan LR, Detre JA, Edelman RR, Jaigobin C, et al. Evidence-based 
guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: 
Report of the therapeutics and technology assessment subcommittee of the american academy of 
neurology. Neurology. 2010; 75:177–185. [PubMed: 20625171] 
15. Agarwal S, Jones PS, Alawneh JA, Antoun NM, Barry PJ, Carrera E, et al. Does perfusion 
computed tomography facilitate clinical decision making for thrombolysis in unselected acute 
patients with suspected ischaemic stroke? Cerebrovasc Dis. 2011; 32:227–233. [PubMed: 
21860235] 
16. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A 
randomized trial of intraarterial treatment for acute ischemic stroke. New Engl J Med. 2015; 
372:11–20. [PubMed: 25517348] 
Luby et al. Page 11
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Luby et al. Page 12
Ta
bl
e 
1
CT
 v
er
su
s M
RI
 se
le
ct
io
n 
ac
ro
ss
 c
lin
ic
al
 sc
en
ar
io
s a
nd
 ti
m
e 
w
in
do
w
s
C
lin
ic
al
 sc
en
ar
io
 #
1:
 P
at
ie
nt
 is
 6
5 
ye
ar
s 
o
ld
 A
lte
re
d 
le
ve
l o
f c
on
sc
io
us
ne
ss
, 
a
ph
as
ia
, d
en
se
 r
ig
ht
 h
em
ip
le
gi
a 
w
ith
 
se
n
so
ry
 d
ef
ic
it 
N
IH
SS
 o
f 2
1
C
lin
ic
al
 sc
en
ar
io
 #
2:
 P
at
ie
nt
 is
 6
5 
ye
ar
s 
o
ld
 A
lte
re
d 
le
ve
l o
f c
on
sc
io
us
ne
ss
, a
ph
as
ia
, 
de
ns
e 
ri
gh
t h
em
ip
le
gi
a 
w
ith
 se
ns
or
y 
de
fic
it 
N
IH
SS
 o
f 2
1 
w
ith
 ea
rl
y 
im
pr
ov
em
en
t t
o 
5
C
lin
ic
al
 sc
en
ar
io
 #
3:
 P
at
ie
nt
 is
 6
5 
ye
ar
s 
o
ld
 F
ac
ia
l w
ea
kn
es
s, 
m
ild
 li
m
b 
w
ea
kn
es
s 
N
IH
SS
 o
f 5
C
lin
ic
al
 sc
en
ar
io
 #
4:
 P
at
ie
nt
 is
 6
5 
ye
ar
s 
o
ld
 F
ac
ia
l w
ea
kn
es
s, 
he
m
ip
ar
es
is 
N
IH
SS
 o
f 1
0
C
T
M
R
I
C
T 
an
d 
M
R
I
C
T
M
R
I
C
T 
an
d 
M
R
I
C
T
M
R
I
C
T 
an
d 
M
R
I
C
T
M
R
I
C
T 
an
d 
M
R
I
0–
3 
h
71
%
 (5
75
)
8%
 (6
5)
21
%
 (1
67
)
67
%
 (1
70
)
10
%
 (2
4)
23
%
 (5
8)
65
%
 (3
57
)
9%
 (5
2)
26
%
 (1
41
)
68
%
 (1
66
)
9%
 (2
1)
23
%
 (5
5)
6 
h
55
%
 (3
87
)
19
%
 (1
36
)
26
%
 (1
84
)
55
%
 (1
29
)
19
%
 (4
5)
25
%
 (5
9)
51
%
 (1
97
)
24
%
 (9
2)
25
%
 (9
9)
54
%
 (1
25
)
19
%
 (4
5)
27
%
 (6
1)
6-
h 
po
st 
ET
53
%
 (1
73
)
21
 %
 (6
8)
26
%
 (8
7)
50
%
 (5
3)
25
%
 (2
6)
25
%
 (2
7)
45
%
 (8
7)
26
%
 (5
1)
29
%
 (5
6)
49
%
 (5
1)
25
%
 (2
6)
26
%
 (2
9)
10
 h
58
%
 (1
33
)
18
%
 (4
2)
24
%
 (5
6)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t 
th
is 
tim
e 
w
in
do
w
58
%
 (1
33
)
20
%
 (4
5)
22
%
 (5
1)
55
%
 (1
28
)
19
%
 (4
3)
26
%
 (6
0)
W
ak
e-
up
43
%
 (9
8)
27
%
 (6
2)
30
%
 (7
0)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t 
th
is 
tim
e 
w
in
do
w
44
%
 (1
00
)
27
%
 (6
3)
29
%
 (6
6)
41
%
 (9
3)
28
%
 (6
3)
31
%
 (7
0)
CT
: C
om
pu
te
d 
To
m
og
ra
ph
y;
 M
RI
: M
ag
ne
tic
 R
es
on
an
ce
 Im
ag
in
g;
 N
IH
SS
: N
at
io
na
l I
ns
tit
ut
es
 o
f H
ea
lth
 S
tro
ke
 S
ca
le
.
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Luby et al. Page 13
Ta
bl
e 
2
Pa
re
nc
hy
m
al
, v
as
cu
la
r, 
an
d 
pe
rfu
sio
n 
im
ag
in
g 
se
le
ct
io
n 
us
in
g 
ei
th
er
 C
T 
or
 M
RI
 a
cr
os
s c
lin
ic
al
 sc
en
ar
io
s a
nd
 ti
m
e 
w
in
do
w
s
C
lin
ic
al
 sc
en
ar
io
 #
1:
 P
at
ie
nt
 is
 6
5 
ye
ar
s 
o
ld
 A
lte
re
d 
le
ve
l o
f c
on
sc
io
us
ne
ss
, 
a
ph
as
ia
, d
en
se
 r
ig
ht
 h
em
ip
le
gi
a 
w
ith
 
se
n
so
ry
 d
ef
ic
it 
N
IH
SS
 o
f 2
1
C
lin
ic
al
 sc
en
ar
io
 #
2:
 P
at
ie
nt
 is
 6
5 
ye
ar
s 
o
ld
 A
lte
re
d 
le
ve
l o
f c
on
sc
io
us
ne
ss
, 
a
ph
as
ia
, d
en
se
 r
ig
ht
 h
em
ip
le
gi
a 
w
ith
 
se
n
so
ry
 d
ef
ic
it 
N
IH
SS
 o
f 2
1 
w
ith
 ea
rl
y 
im
pr
ov
em
en
t t
o 
5
C
lin
ic
al
 sc
en
ar
io
 #
3:
 P
at
ie
nt
 is
 6
5 
ye
ar
s 
o
ld
 F
ac
ia
l w
ea
kn
es
s, 
m
ild
 li
m
b 
w
ea
kn
es
s 
N
IH
SS
 o
f 5
C
lin
ic
al
 sc
en
ar
io
 #
4:
 P
at
ie
nt
 is
 6
5 
ye
ar
s 
o
ld
 F
ac
ia
l w
ea
kn
es
s, 
he
m
ip
ar
es
is 
N
IH
SS
 o
f 1
0
Pa
re
nc
hy
m
al
V
as
cu
la
r
Pe
rf
us
io
n
Pa
re
nc
hy
m
al
V
as
cu
la
r
Pe
rf
us
io
n
Pa
re
nc
hy
m
al
V
as
cu
la
r
Pe
rf
us
io
n
Pa
re
nc
hy
m
al
V
as
cu
la
r
Pe
rf
us
io
n
0–
3 
h
25
%
 (2
03
)
37
%
 (2
99
)
38
%
 (3
05
)
21
%
 (5
3)
37
%
 (9
2)
42
%
 (1
07
)
19
%
 (1
02
)
38
%
 (2
10
)
43
%
 (2
38
)
28
%
 (6
8)
32
%
 (7
7)
40
%
 (9
7)
6 
h
19
%
 (1
38
)
23
%
 (1
60
)
56
%
 (3
94
)
18
%
 (4
3)
28
%
 (6
4)
54
%
 (1
26
)
19
%
 (7
4)
28
%
 (1
10
)
53
%
 (2
38
)
19
%
 (4
4)
27
%
 (6
2)
54
%
 (1
26
)
6-
h 
po
st 
ET
12
%
 (3
8)
25
%
 (8
3)
63
%
 (2
07
)
11
%
 (1
2)
22
%
 (2
3)
67
%
 (7
1)
10
%
 (1
9)
26
%
 (5
0)
64
%
 (1
25
)
8%
 (9
)
25
%
 (2
6)
67
%
 (7
1)
10
 h
37
%
 (8
5)
24
%
 (5
5)
39
%
 (9
1)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s 
tim
e 
w
in
do
w
38
%
 (8
8)
28
%
 (6
3)
34
%
 (7
8)
32
%
 (7
3)
29
%
 (6
8)
39
%
 (8
9)
W
ak
e-
up
15
.5
%
 (3
6)
25
.5
%
 (5
9)
59
%
 (1
35
)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s 
tim
e 
w
in
do
w
27
%
 (6
2)
24
%
 (5
5)
49
%
 (1
12
)
18
%
 (4
2)
24
%
 (5
4)
58
%
 (1
31
)
CT
: C
om
pu
te
d 
To
m
og
ra
ph
y;
 E
T:
 E
nd
ov
as
cu
la
r T
ria
l; 
M
RI
: M
ag
ne
tic
 R
es
on
an
ce
 Im
ag
in
g;
 N
IH
SS
: N
at
io
na
l I
ns
tit
ut
es
 o
f H
ea
lth
 S
tro
ke
 S
ca
le
.
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Luby et al. Page 14
Ta
bl
e 
3
Tr
ea
tm
en
t d
ec
isi
on
s a
cr
os
s c
lin
ic
al
 sc
en
ar
io
 #
1 
an
d 
tim
e 
w
in
do
w
s
C
lin
ic
al
 sc
en
ar
io
 #
1:
M
1 
oc
cl
us
io
n,
 sm
al
l i
nf
ar
ct
,
la
rg
e 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
1:
IC
A
 o
cc
lu
sio
n,
 sm
al
l i
nf
ar
ct
,
la
rg
e 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
1:
M
1 
oc
cl
us
io
n,
 la
rg
e 
in
fa
rc
t, 
no
 p
en
um
br
a
N
on
e
IV
 o
nl
y
En
do
o
n
ly
IV
 p
lu
s
po
ss
ib
le
en
do
(co
mb
o)
N
o
re
sp
on
se
N
on
e
IV
 o
nl
y
En
do
o
n
ly
IV
 p
lu
s p
os
sib
le
en
do
 (c
om
bo
)
N
o
re
sp
on
se
N
on
e
IV
 o
nl
y
En
do
 o
nl
y
IV
 p
lu
s
po
ss
ib
le
en
do
(co
mb
o)
N
o
re
sp
on
se
0–
3 
h
0%
 (0
)
28
%
 (7
9)
2%
 (7
)
67
%
 (1
90
)
2%
 (6
)
<
1%
 (1
)
27
%
 (7
6)
7%
 (2
1)
59
%
 (1
66
)
6%
 (1
8)
24
%
 (6
8)
32
%
 (9
1)
5%
 (1
3)
30
%
 (8
5)
9%
 (2
5)
6 
h
26
%
 (7
4)
2%
 (7
)
35
%
 (9
8)
20
%
 (5
6)
17
%
 (4
7)
26
%
 (7
4)
4%
 (1
0)
38
%
 (1
08
)
14
%
 (4
0)
18
%
 (5
0)
67
%
 (1
90
)
1%
 (4
)
10
%
 (2
8)
4%
 (1
2)
17
%
 (4
8)
6-
h 
po
st 
ET
18
%
 (2
2)
1%
 (1
)
50
%
 (5
9)
23
%
 (2
7)
8%
 (1
0)
26
%
 (3
1)
0%
 (0
)
47
%
 (5
6)
18
%
 (2
1)
9%
 (1
1)
68
%
 (8
1)
3%
 (3
)
13
%
 (1
5)
7%
 (8
)
10
%
 (1
2)
10
 h
54
%
 (1
52
)
1%
 (3
)
22
%
 (6
2)
5%
 (1
3)
18
%
 (5
2)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
W
ak
e-
up
20
%
 (5
7)
10
%
 (2
7)
24
%
 (6
9)
26
%
 (7
3)
20
%
 (5
6)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Luby et al. Page 15
Ta
bl
e 
4
Tr
ea
tm
en
t d
ec
isi
on
s a
cr
os
s c
lin
ic
al
 sc
en
ar
io
s #
2–
4 
an
d 
tim
e 
w
in
do
w
s
C
lin
ic
al
 sc
en
ar
io
 #
2:
M
1 
oc
cl
us
io
n,
 sm
al
l i
nf
ar
ct
,
sm
a
ll 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 3
:
M
1 
oc
cl
us
io
n,
 sm
al
l i
nf
ar
ct
,
sm
a
ll 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
3:
M
2 
oc
cl
us
io
n,
 sm
al
l
in
fa
rc
t, 
sm
al
l p
en
um
br
a
C
lin
ic
al
 sc
en
ar
io
 #
3:
N
o 
oc
cl
us
io
n,
sm
a
ll 
in
fa
rc
t,
n
o
rm
a
l p
er
fu
sio
n
C
lin
ic
al
 sc
en
ar
io
 #
4:
Ba
sil
ar
 o
cc
lu
sio
n
N
on
e
IV on
ly
En
do
o
n
ly
IV
 p
lu
s
po
ss
ib
le
en
do
(co
mb
o)
N
o
re
sp
on
se
N
on
e
IV on
ly
En
do
o
n
ly
IV
 p
lu
s
po
ss
ib
le
en
do
(co
mb
o)
N
o
re
sp
on
se
N
on
e
IV
 o
nl
y
En
do
o
n
ly
IV
 p
lu
s
po
ss
ib
le
en
do
(co
mb
o)
N
o
re
sp
on
se
N
on
e
IV on
ly
En
do
o
n
ly
IV
 p
lu
s
po
ss
ib
le
en
do
(co
mb
o)
N
o
re
sp
on
se
N
on
e
IV on
ly
En
do
o
n
ly
IV
 p
lu
s
po
ss
ib
le
en
do
(co
mb
o)
N
o
re
sp
on
se
0–
3 
h
6%
 (1
6)
38
%
 (1
06
)
2%
 (6
)
44
%
 (1
24
)
11
%
 (3
0)
4%
 (1
1)
54
%
 (1
51
)
1%
 (4
)
29
%
 (8
1)
12
%
 (3
5)
1%
 (2
)
42
%
 (1
18
)
1%
 (2
)
11
%
 (3
0)
46
%
 (1
30
)
14
%
 (3
9)
38
%
 (1
08
)
<
1%
 (1
)
1%
 (2
)
47
%
 (1
32
)
<
1%
 (1
)
22
%
 (6
2)
7%
 (2
0)
56
%
 (1
57
)
15
%
 (4
2)
6 
h
41
%
 (1
15
)
7%
 (2
0)
24
%
 (6
8)
10
%
 (2
8)
18
%
 (5
1)
51
%
 (1
43
)
6%
 (1
8)
17
%
 (4
8)
8%
 (2
2)
18
%
 (5
1)
37
%
 (1
04
)
12
%
 (3
3)
6%
 (1
6)
2%
 (5
)
44
%
 (1
24
)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
18
%
 (5
1)
1%
 (3
)
39
%
 (1
09
)
24
%
 (6
9)
18
%
 (5
0)
6-
h 
po
st 
ET
31
%
 (3
7)
3%
 (3
)
39
%
 (4
6)
17
%
 (2
0)
11
%
 (1
3)
45
%
 (5
3)
3%
 (4
)
27
%
 (3
2)
14
%
 (1
7)
11
%
 (1
3)
38
%
 (4
6)
11
%
 (1
3)
17
%
 (2
0)
8%
 (9
)
26
%
 (3
1)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
13
%
 (1
5)
2%
 (2
)
45
%
 (5
4)
28
%
 (3
4)
12
%
 (1
4)
10
 h
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
71
%
 (1
99
)
2%
 (7
)
7%
 (1
9)
2%
 (5
)
18
%
 (5
2)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
35
%
 (9
8)
1%
 (2
)
36
%
 (1
01
)
10
%
 (2
9)
18
%
 (5
2)
W
ak
e-
up
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
46
%
 (1
30
)
11
%
 (3
2)
10
%
 (2
9)
11
%
 (3
2)
21
%
 (5
9)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
19
%
 (5
3)
4%
 (1
0)
36
%
 (1
01
)
22
%
 (6
2)
20
%
 (5
6)
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Luby et al. Page 16
Ta
bl
e 
5
Cl
in
ic
al
 tr
ia
l e
nr
ol
lm
en
t d
ec
isi
on
s a
cr
os
s c
lin
ic
al
 sc
en
ar
io
s a
nd
 ti
m
e 
w
in
do
w
C
lin
ic
al
 sc
en
ar
io
 #
1:
M
1 
oc
cl
us
io
n,
 sm
al
l i
nf
ar
ct
,
la
rg
e 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
1:
IC
A
 o
cc
lu
sio
n,
 sm
al
l i
nf
ar
ct
,
la
rg
e 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
1:
M
1 
oc
cl
us
io
n,
la
rg
e 
in
fa
rc
t,
n
o
 p
en
um
br
a
C
lin
ic
al
 sc
en
ar
io
 #
2:
M
1 
oc
cl
us
io
n,
sm
a
ll 
in
fa
rc
t,
sm
a
ll 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
3:
M
1 
oc
cl
us
io
n,
sm
a
ll 
in
fa
rc
t,
sm
a
ll 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
3:
M
2 
oc
cl
us
io
n,
sm
a
ll 
in
fa
rc
t,
sm
a
ll 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
3:
N
o 
oc
cl
us
io
n,
sm
a
ll 
in
fa
rc
t,
n
o
rm
a
l p
er
fu
sio
n
C
lin
ic
al
 sc
en
ar
io
 #
4:
Ba
sil
ar
 o
cc
lu
sio
n
Y
es
N
o
N
o
re
sp
on
se
Y
es
N
o
N
o
re
sp
on
se
Y
es
N
o
N
o
re
sp
on
se
Y
es
N
o
N
o
re
sp
on
se
Y
es
N
o
N
o
re
sp
on
se
Y
es
N
o
N
o
re
sp
on
se
Y
es
N
o
N
o
re
sp
on
se
Y
es
N
o
N
o
re
sp
on
se
0–
3 
h
66
%
 (1
87
)
31
%
 (8
8)
3%
 (7
)
58
%
 (1
63
)
35
%
 (1
00
)
7%
 (1
9)
37
%
 (1
04
)
54
%
 (1
52
)
9%
 (2
6)
47
%
 (1
32
)
41
%
 (1
17
)
12
%
 (3
3)
37
%
 (1
06
)
50
%
 (1
40
)
13
%
 (3
6)
17
%
 (4
9)
37
%
 (1
03
)
46
%
 (1
30
)
3%
 (1
0)
50
%
 (1
40
)
47
%
 (1
32
)
43
%
 (1
21
)
42
%
 (1
18
)
15
%
 (4
3)
6 
h
55
%
 (1
56
)
29
%
 (8
2)
16
%
 (4
4)
50
%
 (1
41
)
33
%
 (9
3)
17
%
 (4
8)
25
%
 (6
9)
58
%
 (1
64
)
17
%
 (4
9)
42
%
 (1
19
)
40
%
 (1
13
)
18
%
 (5
0)
39
%
 (1
09
)
43
%
 (1
21
)
18
%
 (5
2)
22
%
 (6
1)
34
%
 (9
6)
44
%
 (1
25
)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
37
%
 (1
06
)
45
%
 (1
26
)
18
%
 (5
0)
6-
h 
po
st 
ET
50
%
 (5
9)
41
%
 (4
9)
9%
 (1
1)
48
%
 (5
7)
41
%
 (4
9)
11
%
 (1
3)
34
%
 (4
1)
54
%
 (6
4)
12
%
 (1
4)
52
%
 (6
2)
35
%
 (4
2)
13
%
 (1
5)
49
%
 (5
8)
38
%
 (4
6)
13
%
 (1
5)
45
%
 (5
4)
27
%
 (3
2)
28
%
 (3
3)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
44
%
 (5
3)
43
%
 (5
1)
13
%
 (1
5)
10
 h
35
%
 (1
00
)
46
%
 (1
29
)
19
%
 (5
3)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
24
%
 (6
9)
57
%
 (1
60
)
19
%
 (5
3)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
32
%
 (9
1)
49
%
 (1
39
)
19
%
 (5
2)
W
ak
e-
up
56
%
 (1
58
)
25
%
 (7
0)
19
%
 (5
4)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
39
%
 (1
10
)
41
%
 (1
16
)
20
%
 (5
6)
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
40
%
 (1
14
)
40
%
 (1
12
)
20
%
 (5
6)
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Luby et al. Page 17
Ta
bl
e 
6
Cl
in
ic
al
 tr
ia
l e
nr
ol
lm
en
t d
ec
isi
on
s a
cr
os
s c
lin
ic
al
 sc
en
ar
io
 a
nd
 ti
m
e 
w
in
do
w
 in
cl
ud
in
g 
pe
rfu
sio
n 
im
ag
in
g 
se
le
ct
io
ns
 u
sin
g 
CT
 o
r M
RI
C
lin
ic
al
 sc
en
ar
io
 #
1:
 
M
1 
oc
cl
us
io
n,
 sm
al
l 
in
fa
rc
t, 
la
rg
e 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
1:
 
IC
A
 o
cc
lu
sio
n,
 sm
al
l 
in
fa
rc
t, 
la
rg
e 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
1:
 
M
1 
oc
cl
us
io
n,
 la
rg
e 
in
fa
rc
t, 
no
 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
2:
 
M
1 
oc
cl
us
io
n,
 sm
al
l 
in
fa
rc
t, 
sm
al
l 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
3:
 
M
1 
oc
cl
us
io
n,
 sm
al
l 
in
fa
rc
t, 
sm
al
l 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 #
3:
 
M
2 
oc
cl
us
io
n,
 sm
al
l 
in
fa
rc
t, 
sm
al
l 
pe
nu
m
br
a
C
lin
ic
al
 sc
en
ar
io
 
#3
: N
o 
oc
cl
us
io
n,
 
sm
a
ll 
in
fa
rc
t, 
n
o
rm
a
l p
er
fu
sio
n
C
lin
ic
al
 sc
en
ar
io
 #
4:
 
Ba
sil
ar
 o
cc
lu
sio
n
Y
es
N
o
Y
es
N
o
Y
es
N
o
Y
es
N
o
Y
es
N
o
Y
es
N
o
Y
es
N
o
Y
es
N
o
0–
3 
h
76
%
 (7
6)
24
%
 (2
4)
67
%
 (6
8)
33
%
 (3
4)
33
%
 (3
3)
67
%
 (6
7)
58
%
 (6
1)
42
%
 (4
4)
58
%
 (4
6)
42
%
 (3
3)
39
%
 (3
1)
61
%
 (4
9)
5%
 (4
)
95
%
 (7
4)
48
%
 (4
6)
52
%
 (4
9)
6 
h
78
%
 (1
02
)
22
%
 (2
9)
72
%
 (9
3)
28
%
 (3
7)
27
%
 (3
6)
73
%
 (9
5)
59
%
 (7
4)
41
%
 (5
1)
61
%
 (6
2)
39
%
 (3
9)
45
%
 (4
5)
55
%
 (5
6)
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s 
tim
e 
w
in
do
w
50
%
 (6
3)
50
%
 (6
3)
6-
h 
po
st 
ET
48
%
 (3
2)
52
%
 (3
4)
48
%
 (3
2)
52
%
 (3
5)
32
%
 (2
2)
68
%
 (4
7)
59
%
 (4
1)
41
%
 (2
9)
54
%
 (3
3)
46
%
 (2
8)
63
%
 (4
0)
37
%
 (2
3)
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s 
tim
e 
w
in
do
w
49
%
 (3
4)
51
%
 (3
6)
10
 h
65
%
 (5
9)
35
%
 (3
2)
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
51
%
 (4
0)
49
%
 (3
8)
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s 
tim
e 
w
in
do
w
49
%
 (4
4)
51
%
 (4
5)
W
ak
e-
up
79
%
 (1
07
)
21
%
 (2
8)
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
60
%
 (6
7)
40
%
 (4
4)
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s t
im
e 
w
in
do
w
Sc
en
ar
io
 n
ot
 
su
rv
ey
ed
 a
t t
hi
s 
tim
e 
w
in
do
w
53
%
 (7
0)
47
%
 (6
1)
CT
: C
om
pu
te
d 
To
m
og
ra
ph
y;
 M
RI
: M
ag
ne
tic
 R
es
on
an
ce
 Im
ag
in
g.
Int J Stroke. Author manuscript; available in PMC 2016 February 22.
